Mind Medicine MindMed. has filed a patent for a method to manufacture R-MDMA and S-MDMA with high enantiomeric excess (>99% e.e.). The process involves specific steps starting from 5-bromobenzodioxole to yield chirally pure MDMA salts. GlobalData’s report on Mind Medicine MindMed gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Mind Medicine MindMed Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Mind Medicine MindMed, Nanoparticle drug conjugates was a key innovation area identified from patents. Mind Medicine MindMed's grant share as of January 2024 was 4%. Grant share is based on the ratio of number of grants to total number of patents.

Manufacturing r-mdma with >99% enantiomeric excess

Source: United States Patent and Trademark Office (USPTO). Credit: Mind Medicine MindMed Inc

A patent application (Publication Number: US20240010628A1) discloses a method for manufacturing R-MDMA and S-MDMA, two enantiomers of the popular recreational drug MDMA. The process involves a series of steps starting from 5-bromobenzodioxole and includes the formation of Grignard reagents, conversion to chirally pure alcohols, protection of amines, reduction steps, and salt formation. The method ensures >99% enantiomeric excess and offers at least a 30% overall yield for both R-MDMA and S-MDMA. Additionally, the process includes steps for converting the amines to salts for purification or storage purposes.

The patent application further details specific compounds used for protecting amines, reducing steps, and the types of salts that can be formed during the process. The method for manufacturing S-MDMA mirrors that of R-MDMA, with slight variations in the starting materials and intermediates. Both processes aim to produce the desired enantiomer in high purity and yield, ensuring the final product meets stringent quality standards. The inclusion of specific compounds and salts in the claims highlights the precision and reproducibility of the method, making it a valuable contribution to the field of drug manufacturing.

To know more about GlobalData’s detailed insights on Mind Medicine MindMed, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies